PH12012502073A1 - Inhibitors of protein tyrosine kinase activity - Google Patents

Inhibitors of protein tyrosine kinase activity

Info

Publication number
PH12012502073A1
PH12012502073A1 PH1/2012/502073A PH12012502073A PH12012502073A1 PH 12012502073 A1 PH12012502073 A1 PH 12012502073A1 PH 12012502073 A PH12012502073 A PH 12012502073A PH 12012502073 A1 PH12012502073 A1 PH 12012502073A1
Authority
PH
Philippines
Prior art keywords
tyrosine kinase
kinase activity
protein tyrosine
inhibitors
compounds
Prior art date
Application number
PH1/2012/502073A
Other languages
English (en)
Inventor
Norifumi Sato
Frã©Dã©Ric Gaudette
Stephen William Claridge
Masashi Kishida
Franck Raeppel
Michael Mannion
Stã©Phane Raeppel
Yohei Yuki
Lijie Zhan
Arkadii Vaisburg
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of PH12012502073A1 publication Critical patent/PH12012502073A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH1/2012/502073A 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity PH12012502073A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
PCT/CA2011/000394 WO2011127567A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
PH12012502073A1 true PH12012502073A1 (en) 2013-02-11

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2012/502073A PH12012502073A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity
PH1/2012/502070A PH12012502070A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH1/2012/502070A PH12012502070A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Country Status (19)

Country Link
US (3) US8455484B2 (enExample)
EP (2) EP2563794A4 (enExample)
JP (2) JP2013523846A (enExample)
KR (2) KR20130100234A (enExample)
CN (2) CN103025740B (enExample)
AR (2) AR080871A1 (enExample)
AU (2) AU2011241420B2 (enExample)
CA (2) CA2796008A1 (enExample)
CO (2) CO6630193A2 (enExample)
EA (2) EA201291055A1 (enExample)
MX (2) MX2012012032A (enExample)
MY (1) MY157319A (enExample)
NZ (2) NZ602948A (enExample)
PH (2) PH12012502073A1 (enExample)
SG (2) SG184882A1 (enExample)
TW (2) TW201204735A (enExample)
UA (1) UA108878C2 (enExample)
WO (2) WO2011127567A1 (enExample)
ZA (2) ZA201207482B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2635131T3 (es) * 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
BRPI0923670A2 (pt) * 2008-03-05 2013-07-30 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
MY157319A (en) * 2010-04-16 2016-05-31 Methylgene Inc Inhibitors of protein tyrosine kinase activity
US20130090327A1 (en) * 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
WO2016040554A1 (en) 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1904504B1 (en) * 2005-05-20 2014-03-19 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
ES2635131T3 (es) * 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
BRPI0923670A2 (pt) * 2008-03-05 2013-07-30 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
MY157319A (en) * 2010-04-16 2016-05-31 Methylgene Inc Inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
EA201291052A1 (ru) 2013-04-30
EA201291055A1 (ru) 2013-09-30
AR080875A1 (es) 2012-05-16
EP2563794A1 (en) 2013-03-06
ZA201207557B (en) 2013-06-26
JP2013525286A (ja) 2013-06-20
US8455484B2 (en) 2013-06-04
PH12012502070A1 (en) 2015-05-08
ZA201207482B (en) 2013-09-25
CN103025740B (zh) 2015-07-01
EP2563794A4 (en) 2013-12-04
NZ602954A (en) 2014-11-28
NZ602948A (en) 2014-09-26
AR080871A1 (es) 2012-05-16
UA108878C2 (ru) 2015-06-25
MX2012012032A (es) 2012-12-17
US20140315801A1 (en) 2014-10-23
TW201204735A (en) 2012-02-01
CO6630193A2 (es) 2013-03-01
WO2011127565A1 (en) 2011-10-20
US8906852B2 (en) 2014-12-09
CO6640224A2 (es) 2013-03-22
US20110257100A1 (en) 2011-10-20
CN102947315A (zh) 2013-02-27
MY157319A (en) 2016-05-31
SG184883A1 (en) 2012-11-29
EP2563795A4 (en) 2013-10-23
AU2011241422A1 (en) 2012-11-01
TW201204734A (en) 2012-02-01
KR20130058006A (ko) 2013-06-03
AU2011241420B2 (en) 2015-04-16
CN103025740A (zh) 2013-04-03
MX2012012031A (es) 2012-12-17
WO2011127567A1 (en) 2011-10-20
SG184882A1 (en) 2012-11-29
JP2013523846A (ja) 2013-06-17
CA2796008A1 (en) 2011-10-20
KR20130100234A (ko) 2013-09-10
AU2011241422B2 (en) 2015-05-07
CA2796054A1 (en) 2011-10-20
EP2563795A1 (en) 2013-03-06
US20110257175A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
UA101362C2 (en) Protein tyrosine kinase activity inhibitors
PH12012502073A1 (en) Inhibitors of protein tyrosine kinase activity
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
WO2007149427A3 (en) Tyrosine kinase inhibitors
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
TN2014000068A1 (en) Compounds and compositions as c-kit kinase inhibitors
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CA3149282C (en) COMPOSITIONS TO MODULATE THE EXPRESSION OF TAU
MX369472B (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
EP2576549A4 (en) BICYCLIC HETEROARYLATES FORMING KINASE INHIBITORS AND METHODS OF USE
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
MX2013012981A (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
MX352844B (es) Compuestos de quinolina sustituidos y metodos de uso.
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
NO20090608L (no) Tyrosinkinaseinhibitorer
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
PH12014500794A1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
WO2013063458A3 (en) Inhibiting g protein coupled receptor 6 kinase polypeptides
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
WO2014110198A3 (en) Therapeutic indications of kinase inhibitors